NovaBay Pharmaceuticals, Inc. (NBY)
USD 0.49
(-9.24%)
USD 0.49
(-9.24%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -4.8 Million USD | -5.61% |
| 2022 | -7.19 Million USD | 65.98% |
| 2021 | -8.74 Million USD | -1049.57% |
| 2020 | -6.37 Million USD | 88.94% |
| 2019 | -9.33 Million USD | -17.86% |
| 2018 | -7.6 Million USD | -25.31% |
| 2017 | -7.21 Million USD | 18.86% |
| 2016 | -10.86 Million USD | 61.87% |
| 2015 | -20.97 Million USD | -25.61% |
| 2014 | -16.67 Million USD | -25.27% |
| 2013 | -15.17 Million USD | -55.38% |
| 2012 | -7.96 Million USD | -200.16% |
| 2011 | -3.89 Million USD | 27.9% |
| 2010 | -4.08 Million USD | -238.04% |
| 2009 | 3.14 Million USD | 136.61% |
| 2008 | -7.8 Million USD | -39.17% |
| 2007 | -5.2 Million USD | -8.59% |
| 2006 | -5.45 Million USD | -56.93% |
| 2005 | -3.41 Million USD | -29.35% |
| 2004 | -2.8 Million USD | -201.83% |
| 2003 | -929 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -1.55 Million USD | -311.5% |
| 2024 Q2 | -1.04 Million USD | 66.15% |
| 2023 Q1 | -1.68 Million USD | -158.99% |
| 2023 FY | - USD | -5.61% |
| 2023 Q2 | -1.56 Million USD | 7.31% |
| 2023 Q3 | -1.11 Million USD | 28.46% |
| 2023 Q4 | -748 Thousand USD | 32.97% |
| 2022 Q4 | 2.85 Million USD | 443.73% |
| 2022 Q1 | -4.31 Million USD | -38.94% |
| 2022 FY | - USD | 65.98% |
| 2022 Q2 | -2.03 Million USD | 52.93% |
| 2022 Q3 | -830 Thousand USD | 59.15% |
| 2021 Q4 | -3.1 Million USD | -36.45% |
| 2021 FY | - USD | -1049.57% |
| 2021 Q1 | -1.51 Million USD | 13.9% |
| 2021 Q2 | -1.84 Million USD | -22.3% |
| 2021 Q3 | -2.27 Million USD | -23.21% |
| 2020 Q4 | -1.75 Million USD | -279.87% |
| 2020 Q1 | -1.66 Million USD | 18.51% |
| 2020 Q2 | 2.71 Million USD | 263.55% |
| 2020 FY | - USD | 88.94% |
| 2020 Q3 | -462 Thousand USD | -117.02% |
| 2019 Q2 | -630 Thousand USD | 81.59% |
| 2019 Q4 | -2.03 Million USD | 47.01% |
| 2019 FY | - USD | -17.86% |
| 2019 Q1 | -3.42 Million USD | -79.73% |
| 2019 Q3 | -3.84 Million USD | -510.16% |
| 2018 Q2 | -2.48 Million USD | 2.13% |
| 2018 FY | - USD | -25.31% |
| 2018 Q3 | -1.98 Million USD | 20.23% |
| 2018 Q4 | -1.9 Million USD | 4.03% |
| 2018 Q1 | -2.54 Million USD | -7800.0% |
| 2017 Q3 | -1.87 Million USD | -6.61% |
| 2017 Q2 | -1.75 Million USD | 50.23% |
| 2017 Q1 | -3.52 Million USD | -40.68% |
| 2017 FY | - USD | 18.86% |
| 2017 Q4 | 33 Thousand USD | 101.76% |
| 2016 Q1 | -4.19 Million USD | 48.04% |
| 2016 Q4 | -2.5 Million USD | -705.47% |
| 2016 FY | - USD | 61.87% |
| 2016 Q3 | -311 Thousand USD | 82.27% |
| 2016 Q2 | -1.75 Million USD | 58.23% |
| 2015 Q2 | -4.81 Million USD | -3.52% |
| 2015 Q4 | -8.08 Million USD | -48.38% |
| 2015 Q3 | -5.44 Million USD | -13.03% |
| 2015 FY | - USD | -25.61% |
| 2015 Q1 | -4.65 Million USD | 12.27% |
| 2014 Q4 | -5.3 Million USD | -33.8% |
| 2014 Q1 | -4.52 Million USD | 17.96% |
| 2014 FY | - USD | -25.27% |
| 2014 Q2 | -4.51 Million USD | 0.35% |
| 2014 Q3 | -3.96 Million USD | 12.12% |
| 2013 Q4 | -5.51 Million USD | -170.94% |
| 2013 Q2 | -4.17 Million USD | -44.63% |
| 2013 Q3 | -2.03 Million USD | 51.2% |
| 2013 FY | - USD | -55.38% |
| 2013 Q1 | -2.88 Million USD | 14.84% |
| 2012 Q4 | -3.38 Million USD | -1468.98% |
| 2012 FY | - USD | -200.16% |
| 2012 Q1 | -2.35 Million USD | -98.65% |
| 2012 Q2 | -3.44 Million USD | -46.43% |
| 2012 Q3 | -216 Thousand USD | 93.73% |
| 2011 Q4 | -1.18 Million USD | -68.8% |
| 2011 Q2 | 560 Thousand USD | 130.99% |
| 2011 Q1 | -1.8 Million USD | -710.31% |
| 2011 FY | - USD | 27.9% |
| 2011 Q3 | -702 Thousand USD | -225.36% |
| 2010 Q3 | -1.54 Million USD | -43.1% |
| 2010 Q4 | -223 Thousand USD | 85.56% |
| 2010 Q2 | -1.07 Million USD | 28.64% |
| 2010 Q1 | -1.51 Million USD | -142.28% |
| 2010 FY | - USD | -238.04% |
| 2009 Q3 | 7000.00 USD | 104.07% |
| 2009 Q2 | -172 Thousand USD | 32.81% |
| 2009 Q1 | -256 Thousand USD | 83.8% |
| 2009 FY | - USD | 136.61% |
| 2009 Q4 | 3.57 Million USD | 50985.71% |
| 2008 Q1 | -2.93 Million USD | -73.77% |
| 2008 Q4 | -1.58 Million USD | -1.02% |
| 2008 Q3 | -1.56 Million USD | 37.99% |
| 2008 FY | - USD | -39.17% |
| 2008 Q2 | -2.52 Million USD | 14.07% |
| 2007 Q2 | -1.73 Million USD | -57.48% |
| 2007 Q1 | -1.1 Million USD | 80.76% |
| 2007 Q3 | -1.65 Million USD | 4.89% |
| 2007 Q4 | -1.68 Million USD | -2.24% |
| 2007 FY | - USD | -8.59% |
| 2006 Q3 | 208 Thousand USD | 113.93% |
| 2006 FY | - USD | -56.93% |
| 2006 Q2 | -1.49 Million USD | -22.58% |
| 2006 Q1 | -1.21 Million USD | -40.65% |
| 2006 Q4 | -5.73 Million USD | -2856.73% |
| 2005 Q4 | -866 Thousand USD | 0.0% |
| 2005 Q2 | -866 Thousand USD | 0.0% |
| 2005 FY | - USD | -29.35% |
| 2005 Q3 | -866 Thousand USD | 0.0% |
| 2005 Q1 | -866 Thousand USD | 0.0% |
| 2004 FY | - USD | -201.83% |
| 2003 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| AIM ImmunoTech Inc. | -31.67 Million USD | 84.848% |
| Ampio Pharmaceuticals, Inc. | - USD | Infinity% |
| Armata Pharmaceuticals, Inc. | -39.91 Million USD | 87.975% |
| Actinium Pharmaceuticals, Inc. | -51.13 Million USD | 90.612% |
| Azitra, Inc. | -10.67 Million USD | 55.028% |
| Can-Fite BioPharma Ltd. | -8.18 Million USD | 41.32% |
| Chromocell Therapeutics Corporation | -6.86 Million USD | 30.052% |
| Calidi Biotherapeutics, Inc. | -28.6 Million USD | 83.217% |
| CEL-SCI Corporation | -27.56 Million USD | 82.584% |
| iBio, Inc. | -14.02 Million USD | 65.766% |
| Lineage Cell Therapeutics, Inc. | -24.73 Million USD | 80.593% |
| MAIA Biotechnology, Inc. | -20.18 Million USD | 76.217% |
| Matinas BioPharma Holdings, Inc. | -22.82 Million USD | 78.97% |
| Navidea Biopharmaceuticals, Inc. | -13.87 Million USD | 65.406% |
| NanoViricides, Inc. | -7.75 Million USD | 38.121% |
| Oragenics, Inc. | -20.87 Million USD | 77.009% |
| BiomX Inc. | -22.81 Million USD | 78.961% |
| BiomX Inc. | -22.81 Million USD | 78.961% |
| Protalix BioTherapeutics, Inc. | 11.65 Million USD | 141.198% |
| Palatin Technologies, Inc. | -29.03 Million USD | 83.466% |
| Scorpius Holdings, Inc. | -35.08 Million USD | 86.318% |